Lange补充道："我们对这些数据感到兴奋，这是下一代胰淀素疗法首个3期临床数据，结果展现出前 景，我们期待在专门的3期RENEW项目中进一步验证Cagrilintide的潜力。" 周二，诺和诺德(NVO.US)涨逾2%，报57.12美元。消息面上，9月16日，诺和诺德表示，其新型减肥药 Cagrilintide在一项晚期临床试验中展现出良好结果。诺和诺德称，一项三期试验的早期分析显示，每周 一次的Cagrilintide单药注射在68周后帮助患者平均减重11.8%，而安慰剂组仅为2.3%。 诺和诺德首席科学官、研发执行副总裁Martin Holst Lange在声明中表示："在我们的临床试验中， Cagrilintide实现了显著减重，其机制不同于已批准的肥胖药物，并且耐受性良好。" Cagrilintide是一种新型减肥疗法，与现有的GLP-1类药物(如诺和诺德的司美格鲁肽和礼来的替尔泊肽) 不同，它是一种长效胰淀素类似物，通过模拟与胰岛素在胰腺中共同分泌的激素来增加饱腹感。 ...

Cagrilintide是一种新型减肥疗法，与现有的GLP-1类药物(如诺和诺德的司美格鲁肽和礼来的替尔泊肽) 不同，它是一种长效胰淀素类似物，通过模拟与胰岛素在胰腺中共同分泌的激素来增加饱腹感。 智通财经APP获悉，周二，诺和诺德(NVO.US)涨逾2%，报57.12美元。消息面上，9月16日，诺和诺德 表示，其新型减肥药Cagrilintide在一项晚期临床试验中展现出良好结果。诺和诺德称，一项三期试验的 早期分析显示，每周一次的Cagrilintide单药注射在68周后帮助患者平均减重11.8%，而安慰剂组仅为 2.3%。 Lange补充道："我们对这些数据感到兴奋，这是下一代胰淀素疗法首个3期临床数据，结果展现出前 景，我们期待在专门的3期RENEW项目中进一步验证Cagrilintide的潜力。" 诺和诺德首席科学官、研发执行副总裁Martin Holst Lange在声明中表示："在我们的临床试验中， Cagrilintide实现了显著减重，其机制不同于已批准的肥胖药物，并且耐受性良好。" ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

The Club's 10 things to watch Tuesday, Sept. 16 — Today's newsletter was written by Jeff Marks, the Club's director of portfolio analysis. 1. The S & P 500 and Nasdaq are set for a higher open this morning, aiming to extend yesterday's gains. Both indexes closed at record highs to kick off the week. Retail sales increased 0.6% month over month in August, the Census Bureau said, exceeding expectations of a 0.2% gain. It's the last key economic reading ahead of the Federal Reserve's interest rate decision tom ...

The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.Novo Nordisk on Wednesday flagged promising late-stage trial results for its new Cagrilinitide obesity treatment, as the Danish pharmaceutical giant seeks a next-generation alternative to its blockbuster Wegovy weight-loss drug.Early analysis from a phase ...